NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
Clinical Trials
10 trialsNCT05432934 2023-12-07
TAP-DEX
University of Saskatchewan
Phase 1/2 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05441761 2022-07-01
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04891744 2021-05-18
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
Phase 1/2 Unknown
NCT04762745 2021-02-21
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT01010243 2012-05-30
MM03
University of Regensburg
Phase 1/2 Unknown
NCT00431990 2011-08-12
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown